A Phase 3 interventional study of Everolimus 0.25 and 0.75 mg tablets and Cyclosporine very low dose (150-300 ng/mL) microemulsion in Transplantation Infection, sponsored by Novartis Pharmaceuticals. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-05-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to allow the continuation of everolimus treatment in patients who have completed the core study (NCT00170885) and to collect long-term safety, tolerability, and efficacy data in a group of patients treated with the upper everolimus target levels plus very low dose cyclosporin in comparison with the standard everolimus target levels plus low dose cyclosporin in patients with renal transplantation.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 8-12 ng/mL. Patients also received a very low dose of cyclosporine (150-300 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 200 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
Drug: Everolimus 0.25 and 0.75 mg tablets · Drug: Cyclosporine very low dose (150-300 ng/mL) microemulsion
Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 3-8 ng/mL. Patients also received a low dose of cyclosporine (350-500 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 400 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
Drug: Everolimus 0.25 and 0.75 mg tablets · Drug: Cyclosporine low dose (350-500 ng/mL) microemulsion
The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
Drug page: Cyclosporine
The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Also known as: Neoral
Drug page: Cyclosporine
The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Also known as: Neoral
Number of Participants With Biopsy-proven Acute Rejection
A graft core biopsy was performed on all suspected acute rejection episodes within 48 hours. Biopsies were read by the local pathologist according to the 1997 Banff criteria. A biopsy-proven acute rejection was be defined as a biopsy graded IA, IB, IIA, IIB, or III.
Time frame: Baseline to end of study (Month 24)
Renal Function Assessed by Creatinine Clearance
Renal function was assessed by measuring serum creatinine and by computing creatinine clearance using the formula of Cockcroft-Gault.
Time frame: Month 12, Month 18, and Month 24
Number of Participants Who Died, Number of Participants Who Lost Their Graft, and Number of Participants Who Died or Lost Their Graft
A participant lost his graft if he/she started dialysis and was not able to subsequently be removed from dialysis or underwent graft nephrectomy.
Time frame: Baseline to end of study (Month 24)
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Deaths
Safety was assessed using reports of adverse events of all participants in this study. Serious adverse events are those events that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.
Time frame: Baseline to end of study (Month 24)
This study was an 18-month extension to the 6-month core study NCT01276457. All patients who were receiving treatment at the end of the core study and signed the informed consent of the extension study were included. Patients received the same treatment in the extension study that they received in the core study.
| Milestone | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine |
|---|---|---|
| Started | 142 | 143 |
| Completed | 129 | 123 |
| Not completed | 13 | 20 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Administrative problems | 1 | 1 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Lack of efficacy | 3 | 12 |
| Milestone | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine |
|---|---|---|
| Started | 111 | 112 |
| Completed | 105 | 110 |
| Not completed | 6 | 2 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 3 | 1 |
A graft core biopsy was performed on all suspected acute rejection episodes within 48 hours. Biopsies were read by the local pathologist according to the 1997 Banff criteria. A biopsy-proven acute rejection was be defined as a biopsy graded IA, IB, IIA, IIB, or III.
| Participants | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine |
|---|---|---|
| Number of Participants With Biopsy-proven Acute Rejection | 21 | 21 |
Renal function was assessed by measuring serum creatinine and by computing creatinine clearance using the formula of Cockcroft-Gault.
| mL/min | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine |
|---|---|---|
| Month 12 (n=111, 111) | 61.26 ± 22.06 | 62.50 ± 20.70 |
| Month 18 (n=108, 108) | 60.90 ± 22.85 | 62.80 ± 21.18 |
| Month 24 (n=106, 110) | 61.92 ± 25.37 | 63.76 ± 21.71 |
A participant lost his graft if he/she started dialysis and was not able to subsequently be removed from dialysis or underwent graft nephrectomy.
| Participants | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine |
|---|---|---|
| Died | 2 | 3 |
| Lost graft | 6 | 15 |
| Died or lost graft | 8 | 18 |
Safety was assessed using reports of adverse events of all participants in this study. Serious adverse events are those events that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.
| Partcipants | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine |
|---|---|---|
| AEs | 142 | 143 |
| Infection | 95 | 101 |
| Clinically significant AEs | 58 | 53 |
| SAEs | 85 | 90 |
| Died | 2 | 3 |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Upper Everolimus Blood Target + Very Low Dose Cyclosporine | — | 85/142 (59.9%) | 142/142 (100%) |
| Standard Everolimus Blood Target + Low Dose Cyclosporine | — | 90/143 (62.9%) | 142/143 (99.3%) |
| Event | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine |
|---|---|---|
| PyrexiaGeneral disorders | 13/142 | 17/143 |
| Blood creatinine increasedInvestigations | 13/142 | 7/143 |
| LymphoceleVascular disorders | 12/142 | 5/143 |
| Transplant rejectionImmune system disorders | 7/142 | 12/143 |
| Kidney transplant rejectionImmune system disorders | 11/142 | 9/143 |
| Urinary tract infectionInfections and infestations | 7/142 | 4/143 |
| Renal impairmentRenal and urinary disorders | 3/142 | 6/143 |
| AnaemiaBlood and lymphatic system disorders | 3/142 | 5/143 |
| Complications of transplanted kidneyInjury, poisoning and procedural complications | 0/142 | 5/143 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/142 | 5/143 |
| Event | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 82/142 | 73/143 |
| Urinary tract infectionInfections and infestations | 69/142 | 81/143 |
| DyslipidaemiaMetabolism and nutrition disorders | 66/142 | 55/143 |
| PyrexiaGeneral disorders | 32/142 | 40/143 |
| Oedema peripheralGeneral disorders | 37/142 | 36/143 |
| HypocalcaemiaMetabolism and nutrition disorders | 33/142 | 19/143 |
| HypertensionVascular disorders | 32/142 | 29/143 |
| Complications of transplanted kidneyInjury, poisoning and procedural complications | 23/142 | 31/143 |
| HypokalaemiaMetabolism and nutrition disorders | 23/142 | 31/143 |
| HyperuricaemiaMetabolism and nutrition disorders | 30/142 | 30/143 |
| Age Continuous(Years) | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine | Total |
|---|---|---|---|
| Mean | 45.3 ± 12.2 | 45.7 ± 10.2 | 45.5 ± 11.2 |
| Sex: Female, Male(Participants) | Upper Everolimus Blood Target + Very Low Dose Cyclosporine | Standard Everolimus Blood Target + Low Dose Cyclosporine | Total |
|---|---|---|---|
| Female | 40 | 37 | 77 |
| Male | 71 | 75 | 146 |
No study locations are listed for this record.
The record gives a start of May 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine